Clinical Trial Update: Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 study of bevacizumab, idarubicin, and cytarabine in patients with blast phase chronic myeloid leukemia (including BCR-ABL1-positive cases) was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blast Phase Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia Bcr-abl1 Positive

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Status: TERMINATED